Compare PEB & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PEB | DFTX |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | United States |
| Employees | 60 | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | N/A | N/A |
| Metric | PEB | DFTX |
|---|---|---|
| Price | $14.11 | $23.29 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | $12.59 | ★ $39.71 |
| AVG Volume (30 Days) | ★ 2.4M | 1.7M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.25 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.56 | $14.62 |
| 52 Week High | $14.23 | $23.41 |
| Indicator | PEB | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 69.45 | 74.64 |
| Support Level | $10.21 | $16.37 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.34 | 1.31 |
| MACD | 0.11 | 0.22 |
| Stochastic Oscillator | 96.00 | 64.88 |
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).